There is some agreement within the multiple myeloma (MM) community regarding the importance of combination chemotherapy, transplant, personalized therapy and minimal residual disease. These hot topics are explored in this intriguing panel discussion at the Myeloma 2017 meeting in Edinburgh, UK by Jonathan Kaufman, MD from Emory University School of Medicine, Atlanta, GA, Faith Davies, MD, MRCP, MRCPath, FRCPath from UAMS Myeloma Institute, Little Rock, AR and Peter Voorhees, MD from the Levine Cancer Institute, Charlotte, NC. The panel also discuss the controversy of treating high-risk smoldering MM patients, and highlight novel studies and combination treatments for MM.
Multiple myeloma: consensuses and controversies
